Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2019

Filed with the SEC on Aug 13, 2019 and accepted by EDGAR at Aug 12, 2019, 21:57 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2018-05-01 to 2019-04-30$0us-gaap:Revenues
Research and development12 months2018-05-01 to 2019-04-30$460.1kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2018-05-01 to 2019-04-30−$4.1mus-gaap:OperatingIncomeLoss
Income tax12 months2018-05-01 to 2019-04-30$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2018-05-01 to 2019-04-30−$4.1mus-gaap:NetIncomeLoss
Diluted EPS12 months2018-05-01 to 2019-04-30$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)12 months2018-05-01 to 2019-04-301,100,104,338 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2018-05-01 to 2019-04-30−$2.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-04-30$515.3kus-gaap:Cash
Current assetsAt period end2019-04-30$653.4kus-gaap:AssetsCurrent
Total assetsAt period end2019-04-30$5.8mus-gaap:Assets
Current liabilitiesAt period end2019-04-30$742.9kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-04-30$742.9kus-gaap:Liabilities
Shareholders' equityAt period end2019-04-30$5.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-19-002559. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.